Search

Your search keyword '"Roberto Freilone"' showing total 7 results
Start Over Author "Roberto Freilone" Publisher wiley
7 results on '"Roberto Freilone"'

1. Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study

Author

Irene Dogliotti, Veronica Peri, Michele Clerico, Francesco Vassallo, Davide Musto, Silvio Mercadante, Simone Ragaini, Barbara Botto, Mario Levis, Mattia Novo, Marco Ghislieri, Luca Molinaro, Umberto Mortara, Chiara Consoli, Alessio Lonardo, Giulia Bondielli, Simone Ferrero, Roberto Freilone, Umberto Ricardi, Benedetto Bruno, and Federica Cavallo

Subjects
chemotherapy, diffuse large B cell lymphoma, real world, refractory disease, relapse, rituximab, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Relapse and refractory (R/R) rates after first‐line R‐CHOP in diffuse large B cell lymphomas (DLBCL) are ~40% and ~15% respectively. Aims We conducted a retrospective real‐world analysis aimed at evaluating clinical outcomes of R/R DLBCL patients. Material and Methods Overall, 403 consecutive DLBCL patients treated in two large hematological centers in Torino, Italy were reviewed. Results At a median follow up of 50 months, 5‐year overall survival from diagnosis (OS‐1) was 66.5%, and 2‐year progression free survival (PFS‐1) was 68%. 134 (34.4%) patients relapsed (n = 46, 11.8%) or were refractory (n = 88, 22.6%) to R‐CHOP. Most employed salvage treatments included platinum salt‐based regimens in 38/134 (28.4%), lenalidomide in 14 (10.4%). Median OS and PFS after disease relapse or progression (OS‐2 and PFS‐2) were 6.7 and 5.1 months respectively. No significant difference in overall response rate, OS‐2 or PFS‐2 in patients treated with platinum‐based regimens versus other regimens was observed. By multivariate analysis, age between 60 and 80 years, germinal center B cell type cell of origin and extranodal involvement of

Published
2024
Full Text
View/download PDF

4. PB2057: THE COMBINATION OF ANTI-COMPLEMENT THERAPY AND CYCLOSPORINE +/- ELTROMBOPAG IN PNH IS EFFECTIVE AND SAFE: A REAL-LIFE OBSERVATIONAL STUDY.

Author

Federica Catania, Chiara Frairia, Matteo Olivi, Moreno Festuccia, Davide Rapezzi, Barbara Nicolino, Giulia Arrigo, Eleonora Boscaro, Federica DI Biase, Marco Cerrano, Irene Urbino, Eloise Beggiato, Giuseppe Lanzarone, Chiara Maria Dellacasa, Alessandro Busca, Dario Ferrero, Stefano D’ardia, Ernesta Audisio, Roberto Freilone, and Valentina Giai

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

5. <scp>Validation of National Early Warning Score and Quick Sequential</scp> ( <scp>sepsis‐related</scp> ) <scp>Organ Failure Assessment in acute myeloid leukaemia patients treated with intensive chemotherapy</scp>

Author

Chiara Frairia, Barbara Nicolino, Carolina Secreto, Emanuela Messa, Giulia Arrigo, Alessandro Busca, Marco Cerrano, Stefano D'Ardìa, Chiara Dellacasa, Andrea Evangelista, Roberto Freilone, Valentina Giai, Giorgio Priolo, Irene Urbino, and Ernesta Audisio

Subjects
Hematology, General Medicine
Published
2023

6. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes

Author

Paola Omedè, Filippo Marmont, Daniela Gioia, Dario Ferrero, Gianni Cametti, Giuliana Strola, Massimo Geuna, Maria Matilde Ciriello, M. Girotto, Berardino Pollio, Giuseppina Prato, Gianluca Gaidano, Marisa Pautasso, Giuseppe Saglio, Flavia Salvi, Margherita Bonferroni, Patrizia Falco, Alessandro Levis, Patrizia Notari, Roberto Freilone, Alessandra Stacchini, and Carlo Marinone

Subjects
medicine.medical_specialty, Univariate analysis, Pathology, Myeloid, medicine.diagnostic_test, biology, CD117, Myelodysplastic syndromes, Cytogenetics, CD34, Hematology, General Medicine, medicine.disease, Gastroenterology, Flow cytometry, Immunophenotyping, medicine.anatomical_structure, Internal medicine, medicine, biology.protein
Abstract

OBJECTIVES Morphology and cytogenetics are currently used to define prognosis in myelodysplastic syndromes (MDS). However, these parameters have some limits. Flow cytometry has been recently included in the diagnostic panel for MDS, and its prognostic significance is under evaluation. METHODS Marrow aspirates from 424 MDS patients were analyzed by flow cytometry to evaluate the impact of bone marrow cell immunophenotype on overall survival (OS) and leukemia-free survival (LFS). The immature compartment of myeloblasts was analyzed by the quantitative expression of CD34 (

Published
2011

7. Molecular heterogeneity of B-lineage diffuse large cell lymphoma

Author

Umberto Mazza, Barbara Botto, Cristina Pastore, Ernesta Audisio, A. Carbone, Marilena Bertini, Domenico Novero, Luigi Resegotti, Gianluca Gaidano, Paolo De Giuli, Giuseppe Saglio, Susanna Cappia, Giorgio Palestro, Gisella Volpe, Umberto Vitolo, and Roberto Freilone

Subjects
Herpesvirus 4, Human, Cancer Research, Lymphoma, B-Cell, Lineage (genetic), Genes, myc, Biology, medicine.disease_cause, Molecular heterogeneity, Genetic Heterogeneity, immune system diseases, Proto-Oncogene Proteins, hemic and lymphatic diseases, Genetics, medicine, Humans, Gene, Gene Rearrangement, Mutation, Molecular pathogenesis, Cancer, Herpesviridae Infections, Genes, p53, medicine.disease, BCL6, Molecular biology, Genes, bcl-2, DNA-Binding Proteins, Tumor Virus Infections, Diffuse large cell lymphoma, Herpesvirus 8, Human, Proto-Oncogene Proteins c-bcl-6, Chromosomes, Human, Pair 6, Lymphoma, Large B-Cell, Diffuse, Chromosome Deletion, Transcription Factors
Abstract

B-lineage diffuse large cell lymphoma (B-DLCL) arising de novo is characterized by a marked degree of clinical heterogeneity. To determine whether or not the clinical heterogeneity of de novo B-DLCL is reflected by heterogeneity in the molecular features of these tumors, we investigated the pattern of distribution of several genetic lesions in 70 cases of de novo B-DLCL at diagnosis. The panel of genetic lesions tested comprised the molecular alterations most frequently detected in B-DLCL, including rearrangements of BCL2, BCL6, and MYC as well as deletions of 6q and mutations of TP53. One or more genetic lesions were detected in 39/70 cases of B-DLCL. Isolated structural alterations of BCL2, BCL6, 6q or TP53 were detected in 8/70, 10/70, 11/70, and 3/70 cases, respectively. No isolated MYC lesions were detected. Six cases carried different combinations of two genetic lesions, including lesions of BCL2 + BCL6 (1 case), BCL2 + MYC (1 case), BCL2 + 6q (2 cases), or BCL6 + 6q (2 cases). One case had accumulated three genetic lesions, namely a rearrangement of BCL2 and BCL6 and a mutation of TP53. Overall, these data show that multiple distinct patterns of genetic lesions may associate with de novo B-DLCL, indicating that the molecular pathogenesis of this group of lymphomas is characterized by a high degree of molecular heterogeneity. Genes Chromosom Cancer 16:21–30 (1996). © 1996 Wiley-Liss, Inc.

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results